A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
Remy S PetersenLaura BordoneMarc A RiedlRaffi TachdjianTimothy J CraigWilliam R LumryMichael E ManningJonathan A BernsteinJason RaaschBruce L ZurawYiwen DengKenneth B NewmanVeronica J AlexanderCindy LuiEugene SchneiderDanny M CohnPublished in: Allergy (2023)
The 2-year interim results of this phase 2 OLE study of donidalorsen in patients with HAE demonstrated no new safety signals; donidalorsen was well tolerated. There was durable efficacy with a 96% reduction in HAE attacks.